Martin Shkreli Gets Another Margin Call After Blowing Up On A Biotech Short
Martin Shkreli Gets Another Margin Call After Blowing Up On A Biotech Short
YouTube11 min 57 sec
Watch on YouTube
Note: AI-generated summary based on third-party content. Not financial advice. Read more.
Quick Insights

Avoid the heavily margined short in the unnamed biotech: the clinical-data catalyst creates substantial squeeze risk, and the allegations in the transcript are unverified. The mentions of SAVA, IONQ, and CAPR provide no actionable thesis. Treat an NVDA earnings bet as speculative; no outlook or trade plan is provided.

Detailed Analysis

Unnamed Biotech Short

  • The speaker describes a heavily margined short position in an unnamed biotech company, with cancer-drug data expected around an ASH meeting. The timing is inconsistent in the transcript: the data is described as due “in two weeks” and also “tomorrow.”
  • The speaker claims the company “lied about their data” and says covering the short could drive the stock sharply higher. These are claims made in the conversation, not independently verified facts.
  • The dialogue portrays the position as under pressure, with margin calls, possible liquidation, and exposure spread across multiple banks.

Takeaways

  • A short position facing a clinical-data catalyst can carry substantial loss and short-squeeze risk, especially when leveraged. The company and its data are not identified well enough here to assess the investment on its merits.
  • Treat the transcript’s allegations and price comments as unverified; it provides no reliable basis for a specific trade.

Cassava Sciences (SAVA)

  • Cassava is mentioned as one of several prior trades or positions associated with the speaker’s difficulties. The conversation does not provide details about the position, trade direction, or performance.

Takeaways

  • The transcript offers no company-specific analysis or current investment thesis for Cassava. It is not enough to support a buy or sell view.

Quantum-Computing Stocks / IonQ (IONQ)

  • The speaker refers generally to “the quantum” and later names IonQ while discussing past trading activity. No specific thesis, price, or current position is provided.

Takeaways

  • Quantum computing is mentioned only as part of the speaker’s trading history; the transcript does not establish a current recommendation or provide evidence for a view on IonQ.

Capricor Therapeutics (CAPR)

  • The speaker mentions “the capacitor” and later names Capricor while discussing previous trades or positions. No details about the trade or the company’s prospects are given.

Takeaways

  • The reference is too brief to indicate a current bullish or bearish view on Capricor.

NVIDIA (NVDA)

  • The speaker notes that NVIDIA earnings are due in two hours and asks whether to “bet on that.” This is framed as a possible speculative trade, not a stated position or recommendation.

Takeaways

  • The transcript gives no earnings expectations, valuation analysis, or specific trade plan. A short-term bet around earnings is speculative and should not be mistaken for an investment thesis.
Ask about this postAnswers are grounded in this post's content.
Video Description
Sign Up For Godel Terminal: https://app.godelterminal.com/?via=shkreliplanet Use Promo Code: Shkreliplanet For 30% Off The First Month Follow Martin Shkreli On Twitter: https://twitter.com/MartinShkreli Follow Martin Shkreli On Instagram: https://www.instagram.com/martinshkreli15/ Trade on Interactive Brokers: https://tinyurl.com/ye2aj6uz Book Recommendation About Stocks & Investing: Common Stocks and Uncommon Profits By Phil Fisher: https://amzn.to/3MCip3R The Intelligent Investor By Benjamin Graham: https://amzn.to/3Xn7jnY One Up On Wall Street By Peter Lynch: https://amzn.to/3XlrfYx
About Shkreli Planet
Shkreli Planet

Shkreli Planet

By @shkreliplanet